Does Ansuvimab Interact with Live Vaccine Indicated For Prevention Of Zaire Ebolavirus In?
CDI records a moderate classification for Ansuvimab and Live Vaccine Indicated For Prevention Of Zaire Ebolavirus In. The stored summary is: EBANGA may reduce the efficacy of live vaccine. Avoid concurrent administration during EBANGA treatment; interval between administration should follow current vaccination guidelines. The mechanism involves ebanga may inhibit replication of live vaccine virus. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Ansuvimab Class
- Zaire Ebolavirus Glycoprotein-directed Antibody
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
EBANGA may inhibit replication of live vaccine virus
What To Tell Your Doctor or Pharmacist
If you are taking Ansuvimab and your doctor is considering prescribing Live Vaccine Indicated For Prevention Of Zaire Ebolavirus In (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider